Citations

Clear

2960 citation(s) found for "Kim, P".

Defining the Spatial Resolution of Analyte Recovery during Microperfusion-Based Sampling of Brain Parenchyma
Stangler, Luke A, Chang, Su-Youne , Kim, Inyong , Bennet, Kevin E. , Howe, Charles L. , Choi, Jonghoon, Howe, Charles L , Choi, Jonghoon , Kouzani, Abbas Z. , Burns, Terry C. , Gompel, Jamie J. Van , Worrell, Gregory A.

Mayo Clinic

ACS Chemical Neuroscience | August 19, 2024 | Volume: 15 | Issue: 17 | Pages: 3220-3227

10.1021/acschemneuro.4c00410 | PMID 39155540 Get It

31‐GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort
Pazhava, Ani , Jing, Frank Z. , Pittelkow, Mark R. , Kim, Yong-Hun , Jing, Frank Z

Mayo Clinic

International Journal of Dermatology | August 18, 2024 | Volume: 64 | Issue: 3 | Pages: 563-570

10.1111/ijd.17440 | PMID 39154363 Get It

AbstractBackgroundCutaneous melanoma (CM) is a significant health concern because of its high metastatic potential. Gene Expression Profile (GEP) testing, particularly the 31‐GEP test (DecisionDx‐Melanoma), has been increasingly used for risk stratification in CM patients. This study aimed to evaluate the clinical utility and performance of the 31‐GEP test in a real‐world setting.MethodsPatients with CM who underwent 31‐GEP testing from August 2014 to August 2022 at our institution were identified through searches of electronic health records. The study analyzed the influence of 31‐GEP testing on clinical decision‐making related to sentinel lymph node biopsy (SLNB), medical oncology referral, and postdiagnosis surveillance. Kaplan–Meier curves and Cox proportional hazard models were used to elucidate the test's performance, focusing on relapse‐free survival (RFS) and melanoma‐specific survival (MSS).ResultsThe study included 65 CM patients. Dermatologists ordered more than 80% of 31‐GEP tests. In 81.5% of cases, 31‐GEP results did not alter standard clinical management. SLNB decisions were unaffected in 92% of patients with pre‐SLNB 31‐GEP results. Among patients with stage I‐IIA melanoma, 25% of those with high‐risk 31‐GEP results were referred to medical oncology. Contrary to expectations, the rate of nodal metastasis was higher in low‐risk than in high‐risk 31‐GEP cases. Survival analysis showed overlapping RFS and MSS curves between different 31‐GEP classes, suggesting limited prognostic value.ConclusionsThe 31‐GEP test has a limited impact on clinical management decisions and shows limited prognostic value.
Comparative Effectiveness of Dupilumab Versus Sinus Surgery for Chronic Rhinosinusitis With Polyps: Systematic Review and a Meta-Analysis
Hwang, Se Hwan , Kim, Do Hyun , Hwang, Se Hwan , Kim, Do Hyun , Stybayeva, Gulnaz

Mayo Clinic

American Journal of Rhinology & Allergy | August 16, 2024 | Volume: 38 | Issue: 6 | Pages: 428-436

10.1177/19458924241272978 | PMID 39149992 Get It

Background Current treatment paradigms recommend surgical intervention when conventional medical management proves ineffective in resolving chronic rhinosinusitis with nasal polyposis. Objectives To assess and compare the efficacy of dupilumab and functional endoscopic sinus surgery (FESS) for the treatment of chronic rhinosinusitis with nasal polyp (CRSwNP) over time. Methods Studies comparing CRSwNP patients who received dupilumab with those who underwent FESS were included. Outcome measures included the nasal congestion score (NCS), Sino-nasal Outcome Test-22 (SNOT-22), University of Pennsylvania Smell Identification Test-40 (UPSIT-40), and nasal polyp score (NPS). The risk of bias was evaluated using the Newcastle-Ottawa Scale. Results A total of 4 studies with 724 participants were included. The dupilumab group had a superior NCS, but an inferior NPS, compared to the FESS group during the follow-up period. The SNOT-22 score of the dupilumab group was inferior to that of the FESS group until 6 months posttreatment, but the scores were similar at around 1 year. A similar trend was observed for the UPSIT-40 score, but the score of the dupilumab group was higher at around 1 year. Conclusion Functional endoscopic sinus surgery was more effective than dupilumab for several months after treatment. However, at 1 year after treatment, the effects of the 2 treatments became similar, with greater olfactory improvement seen in the dupilumab group.
Multi‐Functional Biomaterial for the Treatment and Prevention of Central Line‐Associated Bloodstream Infections
Keum, Hyeongseop , Albadawi, Hassan , Zhang, Zefu , Çevik, Enes , Öklü, Rahmi , Kim, Jinjoo , Graf, Erin H. , Oklu, Rahmi

Mayo Clinic

Advanced Materials | August 15, 2024 | Volume: 36 | Issue: 46 | Pages: No page available

10.1002/adma.202405805 | PMID 39148150 Get It

AbstractCentral venous catheters are among the most used medical devices in hospitals today. Despite advances in modern medicine, catheter infections remain prevalent, causing significant morbidity and mortality worldwide. Here, SteriGel is reported, which is a multifunctional hydrogel engineered to prevent and treat central line‐associated bloodstream infections (CLABSI). The mechanical properties of SteriGel are optimized to ensure appropriate gelation kinetics, bio‐adhesiveness, stretchability, and recoverability to promote durability upon application and to provide persistent protection against infection. In vitro assays demonstrated that SteriGel exhibits long‐term antimicrobial efficacy and has bactericidal effects against highly resistant patient‐derived pathogens known to be frequently associated with CLABSI. SteriGel outperformed Biopatch, which is a clinically used device for CLABSI, in ex vivo cadaver studies that simulate clinical scenarios. Furthermore, SteriGel has biocompatible, pro‐healing, and anti‐inflammatory properties in vitro and in a rat subcutaneous injection model, suggesting a potential synergistic effect in the prevention and treatment of CLABSI. SteriGel is a multifunctional adherent biomaterial with potent antimicrobial effects for sustained sterility while promoting healing of the catheter incision site to protect against infection.
Clinical and radiographic outcomes after mechanical thrombectomy in medium-vessel posterior cerebral artery occlusions: Subgroup analysis from STAR
Findlay, Matthew C, Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos , Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Park, Min S. , Levitt, Michael R. , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard , Navía, Pedro , Kan, Peter , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Wolfe, Stacey Quintero , Yoshimura, Shinichi , Cuellar-Saenz, Hugo H , Alaraj, Ali , Ezzeldin, Mohamad , Fragata, Isabel , Matouk, Charles , Altschul, David J , Grandhi, Ramesh , Levitt, Michael R , Crosa, Roberto , Navia, Pedro , Almallouhi, Eyad , Findlay, Matthew C. , Jabbour, Pascal , Rai, Ansaar , Shaban, Amir , Goyal, Nitin , Cuellar, Hugo , Howard, Brian M , Alawieh, Ali , Romano, Daniele G, Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Leacy, Reade De , Grandhi, Ramesh

Mayo Clinic

Interventional Neuroradiology | August 14, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241273839 | PMID 39140967 Get It

Background Whereas mechanical thrombectomy (MT) has become standard-of-care treatment for patients with salvageable brain tissue after acute stroke caused by large-vessel occlusions, the results of MT in patients with medium-vessel occlusions (MEVOs), particularly in the posterior cerebral artery (PCA), are not well known. Methods Using data from the international Stroke Thrombectomy and Aneurysm Registry (STAR), we assessed presenting characteristics and clinical outcomes for patients who underwent MT for primary occlusions in the P2 PCA segment. As a subanalysis, we compared the PCA MeVO outcomes with STAR's anterior circulation MeVO outcomes, namely middle cerebral artery (MCA) M2 and M3 segments. Results Of the 9812 patients in STAR, 43 underwent MT for isolated PCA MeVOs. The patients’ median age was 69 years (interquartile range 61–79), and 48.8% were female. The median NIH Stroke Scale score was 9 (range 6–17). After recanalization, 67.4% of patients achieved successful recanalization (modified treatment in cerebral infarction score [mTICI] ≥ 2b), with a first-pass success rate of 44.2%, and 39.6% achieved a modified Rankin score of 0–2 at 90 days. Nine patients (20.9%) had died by the 90-day follow-up. In comparison with M2 and M3 MeVOs, there were no differences in presenting characteristics among the three groups. Patients with PCA MeVOs were less likely to undergo intra-arterial thrombolysis (4.7% PCA vs. 10.1% M2 vs. 16.2% M3, p = 0.046) or to achieve successful recanalization (mTICI ≥ 2b, 67.4%, 86.7%, 82.3%, respectively, p < 0.001); however, there were no differences in the rates of successful first-pass recanalization (44.2%, 49.8%, 52.3%, respectively, p = 0.65). Conclusions We describe the STAR experience performing MT in patients with PCA MeVOs. Our analysis supports that successful first-pass recanalization can be achieved in PCA MEVOs at a rate similar to that in MCA MeVOs, although further study and possible innovation may be necessary to improve successful PCA MeVO recanalization rates.
Comparing the Effectiveness and Applicability of Two Intraoperative Break Scheduling Strategies Using OR-Stretch Web-App
Norasi, Hamid , Zoaktafi, Mojgan , Kim, Joseph , Wang, Tianke , Kim, Joseph Y , Tetteh, Emmanuel , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | August 11, 2024 | Volume: 68 | Issue: 1 | Pages: 532-534

10.1177/10711813241260305 Get It

This study provided additional evidence to support the OR-Stretch Web- App as a potential ergonomic intervention in the operating room. Overall, the ORStretch Web-App was beneficial to surgeons’ physical performance, mental focus, and discomfort. However, improving the Web-App to be user-friendly, and developing strategies to align the microbreaks with appropriate time spots during surgeries to not interrupt surgical workflow are among the key factors that need attention. Additionally, no significant differences in the surgeons’ subjective evaluation of the Break-30 and Break-60 scheduling strategies were found. However, the data and surgeons’ feedback implied that taking microbreaks every 30 min (Break-30 condition) may not be ideal, especially during long or complicated surgical procedures.
KCNQ1 suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome
Bains, Sahej , Giammarino, Lucilla , Nimani, Saranda , Alerni, Nicolò , Tester, David J. , Kim, C.S. John, Christoforou, Nicolas , Louradour, Julien , Beslac, Olgica, Barbieri, Miriam , Matas, Lluis , Hof, Thomas , López, Rubén , Perez‐Feliz, Stefanie , Casalta, L.G. Garcia, Jurgensen, Jacqulyn, Bego, Mariana G. , Keyes, Lisa R., Owens, Jane , Pinkstaff, Jason, Koren, Gideon , Zehender, Manfred, Brunner, Michael, Casoni, Daniela , Brooks, Gabriel , Ackerman, Michael J. , Odening, Katja E. , Brunner, Michael , Praz, Fabien , Haeberlin, Andreas , Ackerman, Michael J , Odening, Katja E , Bains, Sahej , Horváth, András , Parodi, Chiara, Barry, Michael A. , Praz, Fabien

Mayo Clinic

European Heart Journal | August 8, 2024 | Volume: 45 | Issue: 36 | Pages: 3751-3763

10.1093/eurheartj/ehae476 | PMID 39115049 Get It

Abstract Background and Aims Type 1 long QT syndrome (LQT1) is caused by pathogenic variants in the KCNQ1-encoded Kv7.1 potassium channels, which pathologically prolong ventricular action potential duration (APD). Herein, the pathologic phenotype in transgenic LQT1 rabbits is rescued using a novel KCNQ1 suppression-replacement (SupRep) gene therapy. Methods KCNQ1-SupRep gene therapy was developed by combining into a single construct a KCNQ1 shRNA (suppression) and an shRNA-immune KCNQ1 cDNA (replacement), packaged into adeno-associated virus serotype 9, and delivered in vivo via an intra-aortic root injection (1E10 vg/kg). To ascertain the efficacy of SupRep, 12-lead electrocardiograms were assessed in adult LQT1 and wild-type (WT) rabbits and patch-clamp experiments were performed on isolated ventricular cardiomyocytes. Results KCNQ1-SupRep treatment of LQT1 rabbits resulted in significant shortening of the pathologically prolonged QT index (QTi) towards WT levels. Ventricular cardiomyocytes isolated from treated LQT1 rabbits demonstrated pronounced shortening of APD compared to LQT1 controls, leading to levels similar to WT (LQT1-UT vs. LQT1-SupRep, P &lt; .0001, LQT1-SupRep vs. WT, P = ns). Under β-adrenergic stimulation with isoproterenol, SupRep-treated rabbits demonstrated a WT-like physiological QTi and APD90 behaviour. Conclusions This study provides the first animal-model, proof-of-concept gene therapy for correction of LQT1. In LQT1 rabbits, treatment with KCNQ1-SupRep gene therapy normalized the clinical QTi and cellular APD90 to near WT levels both at baseline and after isoproterenol. If similar QT/APD correction can be achieved with intravenous administration of KCNQ1-SupRep gene therapy in LQT1 rabbits, these encouraging data should compel continued development of this gene therapy for patients with LQT1.
Tissue Ablation: Applications and Perspectives (Adv. Mater. 32/2024)
Çevik, Enes , Demirlenk, Yusuf Mert , Atar, Dila , Saini, Gia , Sheth, Rahul A. , Keum, Hyeongseop , Kim, Jinjoo , Deipolyi, Amy R. , Öklü, Rahmi

Mayo Clinic

Advanced Materials | August 8, 2024 | Volume: 36 | Issue: 32 | Pages: No page available

10.1002/adma.202470259 Get It

Perceptions, prevalence, and patterns of cannabis use among cancer patients treated at 12 NCI-Designated Cancer Centers
Ellison, Gary L. , Helzlsouer, Kathy J. , Rosenfield, Sonia , Cullen, Jennifer, Doran, Neal , Ebbert, Jon O. , Egan, Kathleen M. , McDaniels‐Davidson, Corinne , Hernandez-Ortega, Nicholas, Salz, Talya , Vidot, Denise C , Zylla, Dylan M. , Rosenfield, Sonia M , Doran, Neal , McDaniels-Davidson, Corinne , Kim, Yun , Ashare, Rebecca L. , Blaes, Anne , Heffner, Jaimee L. , Lee, Richard T. , McClure, Erin A. , Meghani, Salimah H. , Newcomb, Polly A. , Nugent, Shannon M. , Worster, Brooke K. , Zylla, Dylan

Mayo Clinic

JNCI Monographs | August 7, 2024 | Volume: 2024 | Issue: 66 | Pages: 202-217

10.1093/jncimonographs/lgae029 | PMID 39108244 Get It

Abstract Background The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is often used to ameliorate adverse effects of cancer treatment. Data are limited on the extent and type of use among cancer patients during treatment and the perceived benefits and harms. This multicenter survey was conducted to assess the use of cannabis among cancer patients residing in states with varied legal access to cannabis. Methods A total of 12 NCI-Designated Cancer Centers, across states with varied cannabis-access legal status, conducted surveys with a core questionnaire to assess cannabis use among recently diagnosed cancer patients. Data were collected between September 2021 and August 2023 and pooled across 12 cancer centers. Frequencies and 95% confidence intervals for core survey measures were calculated, and weighted estimates are presented for the 10 sites that drew probability samples. Results Overall reported cannabis use since cancer diagnosis among survey respondents was 32.9% (weighted), which varied slightly by state legalization status. The most common perceived benefits of use were for pain, sleep, stress and anxiety, and treatment side effects. Reported perceived risks were less common and included inability to drive, difficulty concentrating, lung damage, addiction, and impact on employment. A majority reported feeling comfortable speaking to health-care providers though, overall, only 21.5% reported having done so. Among those who used cannabis since diagnosis, the most common modes were eating in food, smoking, and pills or tinctures, and the most common reasons were for sleep disturbance, followed by pain and stress and anxiety with 60%-68% reporting improved symptoms with use. Conclusion This geographically diverse survey demonstrates that patients use cannabis regardless of its legal status. Addressing knowledge gaps concerning benefits and harms of cannabis use during cancer treatment is critical to enhance patient-provider communication.
An magnetic resonance imaging–pathology correlation case report of cardiac sarcoidosis mimicking arrhythmogenic biventricular cardiomyopathy
Kim, B Michelle , Bois, Melanie C. , Munoz, Freddy Del‐Carpio , Rosenbaum, Andrew , Chang, Ian C , Del-Carpio Munoz, Freddy , Rosenbaum, Andrew N , Kim, B Michelle

Mayo Clinic

European Heart Journal - Case Reports | August 5, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1093/ehjcr/ytae395 | PMID 39156954 Get It

Abstract Background Cardiac sarcoidosis (CS) is a granulomatous disease that can manifest as conduction defects, ventricular arrhythmias, and heart failure. The diagnosis of CS is inherently difficult due to variable presentations; as such, endomyocardial biopsy is often required but lacks sensitivity due to patchy myocardial involvement. Moreover, the diagnostic criteria of CS and arrhythmogenic cardiomyopathy overlap, particularly in right-side dominant or biventricular presentations, which further complicates an already challenging differential diagnosis. Case summary A 53-year-old man with no prior chronic medical conditions presented with ventricular tachycardia (VT) and heart failure with reduced ejection fraction. He was found to have biventricular cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance imaging, resulting in an initial diagnosis of arrhythmogenic cardiomyopathy. Implantable cardioverter-defibrillator was placed, but he was readmitted for recurrent VT 2 months later. Despite an aggressive VT therapy (combination of antiarrhythmic drugs, epicardial and endocardial ablation, and stellate ganglion block), he continued with refractory VT and developed cardiogenic shock. Extra-corporeal membrane oxygenation was initiated as a bridge to heart transplantation. Pathology of the explanted heart revealed the underlying disease to be CS. Discussion Cardiac sarcoidosis can mimic arrhythmogenic biventricular cardiomyopathy and may be difficult to distinguish by the proposed diagnostic criteria. High clinical suspicion and thorough investigation are necessary for an earlier diagnosis and initiation of treatment.